母亲肥胖对胎儿心脏筛查的影响:哪种随访策略具有成本效益?
研究构建了非肥胖、肥胖和III级肥胖孕妇三个决策分析模型,比较初始胎儿心脏筛查不理想时五种随访策略的成本效益。结果显示,所有BMI组中最具成本效益的策略均为一次随访超声且不做胎儿超声心动图,蒙特卡洛模拟中该策略在非肥胖、肥胖和III级肥胖模型中分别有97%、93%和86%的试验为最优策略。
要点
- 所有BMI组中,一次随访超声且不做胎儿超声心动图均为最具成本效益的策略。
- 直接转诊胎儿超声心动图虽检出更多先心病胎儿,但超过10万美元/QALY阈值,不具成本效益。
- 蒙特卡洛模拟显示一次随访超声且不做胎儿超声心动图在非肥胖、肥胖和III级肥胖模型中分别有97%、93%和86%的试验为最优。
核心结论
- 对于初始胎儿心脏筛查不理想的非肥胖和肥胖孕妇,最佳先心病随访筛查策略是不再超声检查而立即转诊胎儿超声心动图,但该策略不具成本效益。
- 考虑成本时,一次随访超声且不做胎儿超声心动图是首选策略;蒙特卡洛模拟清晰显示该策略在肥胖和非肥胖孕妇中均为最优。
- 因此,初始心脏筛查不理想的非肥胖和肥胖孕妇均应接受一次随访超声检查。
研究设计与样本
- 研究构建了三个决策分析模型,分别针对非肥胖、肥胖和III级肥胖孕妇,比较初始胎儿心脏筛查不理想时的五种随访策略。
- 五种策略为:不随访超声直接转诊胎儿超声心动图;一次随访超声后若心脏切面仍不理想则转诊胎儿超声心动图;最多两次随访超声后若仍不理想则转诊胎儿超声心动图;一次随访超声且不做胎儿超声心动图;最多两次随访超声且不做胎儿超声心动图。
- 模型设定于美国400万活产的理论队列,旨在识别重大先天性心脏病胎儿,评估新生儿死亡和神经发育残疾相关结局,支付意愿阈值为每质量调整生命年10万美元。
- 进行了基础案例和敏感性分析以及蒙特卡洛模拟。
主要发现
- 在全部BMI组的基础案例模型中,不随访超声直接转诊胎儿超声心动图结局最佳,与非肥胖、肥胖和III级肥胖女性的基线策略(一次随访超声且不做胎儿超声心动图)相比,分别多检出7%、25%和82%的先心病胎儿。
- 不随访超声直接转诊胎儿超声心动图超过每质量调整生命年10万美元的阈值,因此不具成本效益。
- 所有BMI组中具成本效益的策略均为一次随访超声且不做胎儿超声心动图。
- 最多两次随访超声且不做胎儿超声心动图以及最多两次随访超声加胎儿超声心动图均被支配(成本更高且效果更差),一次随访超声加胎儿超声心动图超过成本效益阈值。
- 蒙特卡洛模拟中,一次随访超声且不做胎儿超声心动图在非肥胖、肥胖和III级肥胖模型中分别有97%、93%和86%的试验为最优策略。
关键数值与推荐
- 成本效益支付意愿阈值为每质量调整生命年10万美元。
- 与非肥胖、肥胖和III级肥胖女性的基线策略(一次随访超声且不做胎儿超声心动图)相比,不随访超声直接转诊胎儿超声心动图分别多检出7%、25%和82%的先心病胎儿。
- 蒙特卡洛模拟中一次随访超声且不做胎儿超声心动图在非肥胖、肥胖和III级肥胖模型中分别有97%、93%和86%的试验为最优策略。
临床怎么用
- 作者结论认为,初始心脏筛查不理想的非肥胖和肥胖孕妇均应接受一次随访超声检查。
- 作者结论认为,考虑成本时一次随访超声且不做胎儿超声心动图是首选策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a cost-effectiveness analysis of different follow-up strategies for non-obese and obese women who had incomplete fetal cardiac screening for major congenital heart disease (CHD). METHODS: Three decision-analytic models, one each for non-obese, obese and Class-III-obese women, were developed to compare five follow-up strategies for initial suboptimal fetal cardiac screening. The five strategies were: (1) no follow-up ultrasound (US) examination but direct referral to fetal echocardiography (FE); (2) one follow-up US, then FE if fetal cardiac views were still suboptimal; (3) up to two follow-up US, then FE if fetal cardiac views were still suboptimal; (4) one follow-up US and no FE; and (5) up to two follow-up US and no FE. The models were designed to identify fetuses with major CHD in a theoretical cohort of 4 000 000 births in the USA. Outcomes related to neonatal mortality and neurodevelopmental disability were evaluated. A cost-effectiveness willingness-to-pay threshold was set at US$100 000 per quality-adjusted life year (QALY). Base-case and sensitivity analysis and Monte-Carlo simulation were performed. RESULTS: In our base-case models for all body mass index (BMI) groups, no follow-up US, but direct referral to FE led to the best outcomes, detecting 7%, 25% and 82% more fetuses with CHD in non-obese, obese and Class-III-obese women, respectively, compared with the baseline strategy of one follow-up US and no FE. However, no follow-up US, but direct referral to FE was above the US$100 000/QALY threshold and therefore not cost-effective. The cost-effective strategy for all BMI groups was one follow-up US and no FE. Both up to two follow-up US with no FE and up to two follow-up US with FE were dominated (being more costly and less effective), while one follow-up US with FE was over the cost-effectiveness threshold. One follow-up US and no FE was the optimal strategy in 97%, 93% and 86% of trials in Monte-Carlo simulation for non-obese, obese and Class-III-obese models, respectively. CONCLUSION: For both non-obese and obese women with incomplete fetal cardiac screening, the optimal CHD follow-up screening strategy is no further US and immediate referral to FE; however, this strategy is not cost-effective. Considering costs, one follow-up US and no FE is the preferred strategy. For both obese and non-obese women, Monte-Carlo simulations showed clearly that one follow-up US and no FE was the optimal strategy. Both non-obese and obese women with initial incomplete cardiac screening examination should therefore be offered one follow-up US. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Bak GS, Shaffer BL, Madriago E, et al. Impact of maternal obesity on fetal cardiac screening: which follow-up strategy is cost-effective? Ultrasound Obstet Gynecol. 2020. PMID: 31614030. doi:10.1002/uog.21895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。